TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05026346

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathologic Exercise
Description: 1. In the first phase of the project, a series of 5 active shoulder mobilization exercises characterized by an adequate range of motion will be tested to verify the set up for the video recording.~2. In the second phase shoulder movements will be recorder by a smartphone.~3. A questionnaire will be used and adapted on the basis of which to evaluate the correctness of the exercises performed by each healthy subject / patient. This questionnaire will provide a Clinical Score (CS) which assigns a numerical value to the patient's overall performance for each repetition.~4. The videos of each repetition of exercises performed by the healthy subjects / patients will then be evaluated by two different clinicians, blinded, using the questionnaire.~5. The Artificial Intelligence learning algorithm will be able to output an evaluation score that will be compared with that produced by clinicians.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathologic Exercise
Description: 1. In the first phase of the project, a series of 5 active shoulder mobilization exercises characterized by an adequate range of motion will be tested to verify the set up for the video recording.~2. In the second phase shoulder movements will be recorder by a smartphone.~3. A questionnaire will be used and adapted on the basis of which to evaluate the correctness of the exercises performed by each healthy subject / patient. This questionnaire will provide a Clinical Score (CS) which assigns a numerical value to the patient's overall performance for each repetition.~4. The videos of each repetition of exercises performed by the healthy subjects / patients will then be evaluated by two different clinicians, blinded, using the questionnaire.~5. The Artificial Intelligence learning algorithm will be able to output an evaluation score that will be compared with that produced by clinicians.
Study: NCT00441025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Study: NCT03825133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate
Description: Bone marrow ( 100 ml) is aspirated from proximal tibia, concentrated in Arthrex Angel Centrifuge, and after concentration 6 ml of BMAC is injected in the knee
Study: NCT01390116

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AGE
Description: encapsulated aged garlic extract, 4 capsules per day, 2.56g/day
Study: NCT02202096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education: One-on-one visit
Description: The navigator or surgeon will have a one-on-one visit with he patient to answer any questions.
Study: NCT03825133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukocyte Rich Platelet Rich Plasma
Description: Blood sample is taken ( 100 ml), centrifuged in Arthrex Angel Centrifuge and after double spinning process about 6 ml of PRP is injected in the knee

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Three injections of Cartinorm (1% Sodium Hyaluronat (20mg/2 ml) by Goodwill Pharma) is injected in the knee weekly
Study: NCT02202096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge planning: Assessment of barriers to discharge
Description: Case management will be consulted on the day of surgery. The navigator will perform an assessment of barriers to discharge based on one-on-one interviews with the patient.
Study: NCT02490189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: Twelve week group intervention that includes training in mindfulness meditation, self-compassion and mindful exposure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Group Therapy
Description: Twelve week group intervention that focuses on the interaction between thoughts, feelings, and behaviors.
Study: NCT02688439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sciatic Nerve block
Study: NCT03060603

Intervention type: DRUG
Intervention: Erythropoietin
Description: Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
Study: NCT01963299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 ml Ropivacaine 10% + physiological saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 ml Ropivacaine 10% + Clonidine 1 µg/kg
Study: NCT03050359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets
Study: NCT04159675

Intervention type: BIOLOGICAL
Intervention: osteoblast biology study
Description: Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR

Intervention type: BIOLOGICAL
Intervention: osteoblast biology study
Description: Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR
Study: NCT04691375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY314
Description: Dose of PY314 as a single agent given in a standard 3+3 design.
Study: NCT02688439

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic Nerve block
Study: NCT03050359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438 Placebo
Description: TAK-438 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Placebo
Description: Lansoprazole placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth-Containing Quadruple Therapy
Description: 1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth-Containing Quadruple Therapy
Description: 1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
Study: NCT02688439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sciatic Nerve block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg raised 30°

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distal tourniquet placed on the lower part of the leg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg in a neutral position

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leg in a neutral position
Study: NCT04162834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papaverine
Description: Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
Study: NCT05755750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genipin
Description: Intratendinous genipin injection
Study: NCT02020161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atra
Study: NCT02370355

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02020161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT02370355

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04343079

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET CT
Description: measurement of surgical margins during lumpectomy
Study: NCT03342482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-glutamate diet
Description: The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-glutamate diet
Description: The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
Study: NCT02141646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The main goals of motivational interviewing are to engage clients, elicit change talk, and evoke motivation to make positive changes from the client.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Skills Training
Description: Behavioral Skills Training (BST) is a training package that utilizes instructions, modeling, rehearsal, and feedback in order to teach a new skill.
Study: NCT04987060

Intervention type: DEVICE
Group type: OTHER
Intervention: Intrastromal Fresh Human Lenticule Implantation
Description: The stromal pocket diameter was set 8.0 mm and cap thickness was set to 140 μm from corneal surface and a 2mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 2 mm superior incision. Incision position changed according to the position of the highest K values.
Study: NCT00793676

Intervention type: OTHER
Group type: OTHER
Intervention: spirometry

Intervention type: OTHER
Group type: OTHER
Intervention: blood test

Intervention type: OTHER
Group type: OTHER
Intervention: blood test

Intervention type: OTHER
Group type: OTHER
Intervention: blood test
Study: NCT04048525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CVVHD
Description: CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH
Description: CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter infusion to maintain a theoretical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
Study: NCT04365439

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood plasma
Description: Convalescent plasma after COVID-19
Study: NCT04501198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine
Description: 1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. Xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. The Xiusheng Decoction should be taken twice a day. Traditional exercises will be taken for 35\~40 minutes everyday, 7 times a week. The intervention of Xiusheng Decoction and traditional exercises will be conducted for 8 weeks. All patients will be instructed to follow a good living habits which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moxibustion combined with lifestyle intervention.
Description: 1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.

Intervention type: DEVICE
Group type: OTHER
Intervention: lifestyle intervention
Description: All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
Study: NCT02856269

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc gluconate
Description: Participants will take a daily dose of zinc gluconate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc gluconate
Description: Participants will take a daily dose of zinc gluconate.
Study: NCT04365985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate COVID-19 infection stages. Naltrexone will continue for 1 month post hospital discharge. Patients progressing to requirement for advanced oxygenation will be reassess when sedation and assigned to Ketamine arm. Naltrexone may be reduced to 1.5 mg/day if interfering with sedation and can be held when sedation and symptoms of withdrawal is an issue..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate COVID-19 infection stages. Naltrexone will continue for 1 month post hospital discharge. Patients progressing to requirement for advanced oxygenation will be reassess when sedation and assigned to Ketamine arm. Naltrexone may be reduced to 1.5 mg/day if interfering with sedation and can be held when sedation and symptoms of withdrawal is an issue..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Low dose ketamine hydrochloride given intravenously at a dosage of 0.15 mg/kg body weight for maximum 20 mg every 6 hours, to inpatient participants with advanced oxygenation requirements from either time of admission or time of progression of mild/moderate disease until time participant is stable for discharge, as a rescue treatment. If patient is transferred from the naltrexone or placebo arm, they will continue to receive naltrexone/placebo. Dosage of ketamine may be increased to 0.3 mg/kg body weight, maximum 30 mg every 6 hours, if participant does not respond at the lower dosage. Ketamine can be reduced back to 0.15 mg/kg at the clinical decision of the investigator and when patient has hypertensive emergency, the dose can be held until hypertensive emergency is controlled.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo, given from date of admission through time participant is stable for discharge for inpatient participants in mild/moderate COVID-19 infection stages. Placebo will continue for 1 month post discharge. Participants progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo, given from date of admission through time participant is stable for discharge for inpatient participants in mild/moderate COVID-19 infection stages. Placebo will continue for 1 month post discharge. Participants progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.
Study: NCT00575952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV or IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV or IP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study: NCT04068324

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Care No Nil Per Os
Description: The product name NoNPO is from South Korean company Well life. It contains carbohydrate and is frequently used in preoperative fasting patients in order to alleviate patients' discomfort resulting from empty stomach and thirst. It is also known to decrease insulin resistant.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Care No Nil Per Os
Description: The product name NoNPO is from South Korean company Well life. It contains carbohydrate and is frequently used in preoperative fasting patients in order to alleviate patients' discomfort resulting from empty stomach and thirst. It is also known to decrease insulin resistant.
Study: NCT04200677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monophasic Current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following NMES parameters: (Monophasic Current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (100 Hz) with pulse width 0.5ms applied to the Tibial Nerve
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
Study: NCT01170351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine-A
Description: Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine-A
Description: Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.
Study: NCT01734525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards
Study: NCT03973944

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac resynchronization therapy
Description: Atrio-biventricular pacing to shorten the prolonged PR interval
Study: NCT01590836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single dose administered subcutaneously (s.c., under the skin).
Study: NCT04306354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.
Study: NCT00565110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPt-C intervention
Description: Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
Study: NCT00516386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhIGF-1
Description: 35-40 mcg/k/dose twice daily SC
Study: NCT00711958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575, solution for injection (s.c.)
Description: 1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERYPO®, Janssen-Cilag, solution for injection (s.c.)
Description: 1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
Study: NCT00164281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Daily 300 mg isoniazid supplemented with 25 mg pyridoxine for 6 months vs 36 months.